Prosecution Insights
Last updated: April 19, 2026
Application No. 18/585,786

EVERTING TRANSCATHETER VALVE AND METHODS

Non-Final OA §102
Filed
Feb 23, 2024
Examiner
NGUYEN, VI X
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Edwards Lifesciences Corporation
OA Round
1 (Non-Final)
86%
Grant Probability
Favorable
1-2
OA Rounds
3y 5m
To Grant
99%
With Interview

Examiner Intelligence

Grants 86% — above average
86%
Career Allow Rate
983 granted / 1145 resolved
+15.9% vs TC avg
Moderate +13% lift
Without
With
+13.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
29 currently pending
Career history
1174
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
36.9%
-3.1% vs TC avg
§102
40.1%
+0.1% vs TC avg
§112
11.0%
-29.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1145 resolved cases

Office Action

§102
DETAILED ACTION Election/Restrictions Applicant’s election without traverse of Group 3, claims 14-21 in the reply filed on 12/10/2025 is acknowledged. Claims 1-13 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 12/10/2025. Claim Interpretation The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Specification The abstract of the disclosure is objected to because it contains legal phraseology such as “comprise” in lines 2,4,9. A corrected abstract of the disclosure is required and must be presented on a separate sheet, apart from any other text. See MPEP § 608.01(b). Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of pre-AIA 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language. Claim(s) 14-21 is/are rejected under pre-AIA 35 U.S.C. 102(e) as being anticipated by Benichou et al U.S 2011/0218619. Claim 14: Benichou et al disclose a method comprising: expanding a prosthetic heart valve 2400 at an implantation site, wherein: the prosthetic heart valve comprises a frame at 2402 that includes a first portion coupled to a second portion; transitioning the frame from a non-everted configuration (fig 25 shows the leaflet 2404 and rods 2406 can be flipped i.e., inverted configuration, see paragraph 125) to an everted configuration (fig. 24 shows hinges can allow for inversion or eversion configuration of rods 2406 and leaflets 2404 without deformation of any metallic components, see paragraph 125) by everting the second portion relative to the first portion; and securing the prosthetic heart valve at the implantation site. Claims 15-17: Benichou et al disclose wherein everting the second portion relative to the first portion comprises moving an everter (item 1106, fig. 12 is similar structure as applicant’s item 485, in applicant’s fig. 5b) from a first position to a second position relative to the prosthetic heart valve 2400., wherein: the first position is distally adjacent a distal end of the prosthetic heart valve, and the second position is proximally disposed relative to a proximal end of the prosthetic heart valve., wherein: the prosthetic heart valve defines a valve orifice (at the area 1116, fig. 12), and the everter 1106 is moved through the valve orifice from the first position to the second position. Claims 18-19: Benichou et al disclose the first portion and the second portion are indirectly coupled by a film (it is noted that a flexible sleeve or membrane 1110, fig. 13) extending between the first portion and the second portion, and the film defines a fold region (see applicant’s claim 27) disposed between the first portion and the second portion., wherein everting the second portion relative to the first portion comprises rotating the second portion about the fold region (see applicant’s claim 27) relative to the first portion. Claims 20-21: Benichou et al disclose wherein everting the second portion (see fig. 24) relative to the first portion comprises moving the second portion in a proximal direction relative to the first portion., wherein the first portion extends coaxially, adjacent to, and spaced apart from the second potion when the frame is in the non-everted (see fig. 25) configuration. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to VI X NGUYEN whose telephone number is (571)272-4699. The examiner can normally be reached Monday-Friday (6:30-4:30). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Darwin Erezo can be reached at 571-272-4695. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /VI X NGUYEN/Primary Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Feb 23, 2024
Application Filed
Feb 19, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12582750
METHOD FOR PRODUCING TRANSPLANTABLE ORAL MUCOSA TISSUE
2y 5m to grant Granted Mar 24, 2026
Patent 12575848
Ultrasonic Surgical Tool System Including a Tip Capable of Simultaneous Longitudinal and Torsional Movement and a Console Capable of Applying a Drive Signal to the Tip so the Tip Engages in Substantially Torsional Oscillations
2y 5m to grant Granted Mar 17, 2026
Patent 12569657
SYSTEMS AND METHODS FOR THE TREATMENT AND PREVENTION OF FEMALE PELVIC DYSFUNCTION
2y 5m to grant Granted Mar 10, 2026
Patent 12569234
DEVICES AND METHODS FOR OCCLUDING ABNORMAL OPENINGS IN A PATIENT'S VASCULATURE
2y 5m to grant Granted Mar 10, 2026
Patent 12564656
SPRAYABLE TISSUE ADHESIVE WITH BIODEGRADATION FOR WOUND TREATMENT
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
86%
Grant Probability
99%
With Interview (+13.3%)
3y 5m
Median Time to Grant
Low
PTA Risk
Based on 1145 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month